Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection

References

• Stampfer M J, Colditz G A, Willett W C. Menopause and heart disease: a review. Ann N York Acad Sci 1990; 592: 193–203
   PubMed Web of Science ®Google Scholar
• Eaker E D, Chesbro J H, Sacks F M, et al. Cardiovascular disease in women. Circulation 1993; 88: 1999–2009
   PubMed Web of Science ®Google Scholar
• Wenger N K, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247–56
   PubMed Web of Science ®Google Scholar
• Posthuma WFM, Westendorp RGJ, Vanden-Broucke J P. Cardiovascular effect of hormone replacement therapy in postmenopausal women: is the evidence biased?. Br Med J 1994; 308: 1168–9
   Google Scholar
• Crosignani P G, Kenemans P, Paoletti R, et al. Hormone replacement therapy and the menopause: a European position paper. Eur J Obstet Gynecol Reprod Biol 1997; 74: 67–72
   PubMedGoogle Scholar
• Pines A, Mijatovic V, Van der Mooren M J, et al. Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol 1997; 71: 193–7
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Manson J E, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–61
   PubMed Web of Science ®Google Scholar
• Gruchow H W, Anderson A J, Barboriak J J, et al. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115: 954–63
   PubMed Web of Science ®Google Scholar
• MacFarland K F, Boniface M E, Hornung C A, et al. Risk factors and non-contraceptive estrogen use in women with and without coronary artery disease. Am Heart J 1989; 117: 1209–14
   PubMedGoogle Scholar
• Sullivan J M, Van der Zwaag R, Hughes J P. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988; 108: 358–63
   PubMed Web of Science ®Google Scholar
• Sullivan J M, Van der Zwaag R, Hughes J P, et al. Estrogen replacement and coronary artery disease; effect on survival in postmenopausal women. Arch Intern Med 1990; 150: 2557–62
   PubMed Web of Science ®Google Scholar
• O'Keefe J H, Kim S C, Hall R R, et al. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997; 29: 1–5
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Colditz G A, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998; 280: 605–13
   PubMed Web of Science ®Google Scholar
• Bush T L, Barrett-Connor E, Cowan L D, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–9
   PubMed Web of Science ®Google Scholar
• Venkov C D, Rankin A B, Vaughan D E. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996; 94: 727–33
   PubMed Web of Science ®Google Scholar
• McGill H C. Sex steroid hormone receptors in the cardiovascular system. Postgrad Med 1989; 85: 648–53
   Google Scholar
• Losordo D W, Kearney M, Kim E A, et al. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994; 89: 1501–10
   PubMed Web of Science ®Google Scholar
• Karas R H, Patterson B L, Mendelsohn M E. Human vascular smooth muscle cells contain functional estrogen receptors. Circulation 1994; 89: 1943–50
   PubMed Web of Science ®Google Scholar
• Horwitz K B, Horwitz L D. Canine vascular tissues are targets for androgens, estrogen, progestins and glucocorticoids. J Clin Invest 1982; 69: 750–8
   PubMed Web of Science ®Google Scholar
• Perrot-Applant M, Picard-Groyer M T, Lorenzo G F, et al. Immunocytochemical demonstration of estrogen and progesterone receptors in muscle cells of uterine arteries in rabbits and humans. Endocrinology 1988; 123: 1511–19
   PubMedGoogle Scholar
• Perrot-Applant M, Deng M, Fernandez H, et al. Immunohistochemical localization of estradiol and progesterone receptors in human uterus throughout pregnancy; expression in endometrial blood vessels. J Clin Endocrinol Metab 1994; 78: 216–24
   PubMedGoogle Scholar
• Vane J R, Anggard E E, Botting R M. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27–36
   PubMed Web of Science ®Google Scholar
• Dzau V J, Gibbons G H, Cooke J P, et al. Vascular biology and medicine in the 1990′s: scope, concepts, potentials, and perspectives. Circulation 1993; 87: 705–19
   PubMed Web of Science ®Google Scholar
• Zeiher A M, Drexler H, Wollschlager H, et al. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391–401
   PubMed Web of Science ®Google Scholar
• Panza J A, Quyyumi A A, Brush J E, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22–7
   PubMed Web of Science ®Google Scholar
• Creager M A, Gallagher S J, Girerd X J, et al. Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248–53
   PubMed Web of Science ®Google Scholar
• Casino P R, Kilcoyne C M, Quyyumi A A, et al. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88: 2541–7
   PubMed Web of Science ®Google Scholar
• Stehouwer CDA, Lambert J, Donker AJM, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55–68
   PubMed Web of Science ®Google Scholar
• Ware J A, Heistad D D. Platelet-endothelium interactions. N Engl J Med 1993; 328: 628–35
   PubMed Web of Science ®Google Scholar
• Williams J K, Adams M R, Klopfenstein H S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990; 81: 1680–7
   PubMed Web of Science ®Google Scholar
• Williams J K, Adams M R, Herrington D M, et al. Short-term administration of estrogen and vascular responses of atherosclerotic arteries. J Am Coll Cardiol 1992; 20: 452–7
   PubMed Web of Science ®Google Scholar
• Adams M R, Kaplan J R, Manuck S B, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990; 10: 1051–7
   PubMedGoogle Scholar
• Bell C, Coffey C. Factors influencing estrogen-induced sensitization to acetylcholine of guinea-pig uterine artery. J Reprod Fertil 1982; 66: 133–7
   PubMedGoogle Scholar
• Miller V M, Gisclard V, Vanhoutte P M. Modulation of endothelium-dependent and vascular smooth muscle responses by estrogen. Phlebology 1988; 224: 19–22
   Google Scholar
• Reis S E, Gloth S T, Blumenthal R S, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994; 89: 52–60
   PubMed Web of Science ®Google Scholar
• Gilligan D M, Quyyumi A A, Cannon R O. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89: 2545–51
   PubMed Web of Science ®Google Scholar
• Sarrel P M, Lindsay D, Rosano G M, et al. Angina and normal coronary arteries in women: gynecologic findings. Am J Obstet Gynecol 1992; 167: 467–71
   PubMed Web of Science ®Google Scholar
• Collins P, Rosano GMC, Sarrel P M, et al. 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary artery disease. Circulation 1995; 92: 24–30
   PubMed Web of Science ®Google Scholar
• Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994; 343: 1199–206
   PubMed Web of Science ®Google Scholar
• White M M, Zamudio S, Stevens T, et al. Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. Endocrine Rev 1995; 6: 739–51
   Google Scholar
• Yagi K, Komura S. Inhibitory effect of female hormones on lipid peroxidation. Biochem Int 1986; 13: 1051–5
   PubMedGoogle Scholar
• Simon B C, Cunningham L D, Cohen R A. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation to Ach in isolated rabbit coronary arteries. J Clin Invest 1990; 86: 75–9
   PubMed Web of Science ®Google Scholar
• Kaddoura S, Poole-Wilson P A. Endothelin-1 in heart failure: a new therapeutic target?. Lancet 1996; 348: 418–19
   PubMedGoogle Scholar
• Polderman K H, Stehouwer CDA, van Kamp G J, et al. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429–32
   PubMed Web of Science ®Google Scholar
• Wilcox J G, Hatch I E, Gentzschein E, et al. Endothelin levels decrease after oral and non-oral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril 1997; 67: 273–7
   PubMed Web of Science ®Google Scholar
• Mikkola T, Ranta V, Orpana A, et al. Hormone replacement therapy modifies the capacity of plasma and serum to regulate prostacyclin and endothelin-1 production in human vascular endothelium cells. Fertil Steril 1996; 66: 389–93
   PubMedGoogle Scholar
• Jiang C, Sarrel P M, Lindsay D C, et al. Endothelium-independent relaxation of rabbit coronary artery by 17-beta-oestradiol in vitro. Br J Pharmacol 1991; 104: 1033–7
   PubMed Web of Science ®Google Scholar
• Downing S J, Hollingsworth M, Miller M. The influence of oestrogen and progesterone on the actions of two calcium entry blockers in the rat uterus. J Endocrinol 1988; 118: 251–8
   PubMedGoogle Scholar
• Gilligan D M, Badar D M, Panza J A, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786–91
   PubMed Web of Science ®Google Scholar
• Gangar K F, Vyas S, Whitehead M I, et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 839–42
   PubMed Web of Science ®Google Scholar
• Bourne T, Hillard T C, Whitehead M I, et al. Oestrogens, arterial status, and postmenopausal women. Lancet 1990; 335: 1470–1
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Sarrel P M, Poole-Wilson P A, et al. Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet 1993; 342: 133–6
   PubMed Web of Science ®Google Scholar
• The writing group for the PEPI-trial. Effects of estrogen or estrogen/progestogen regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995; 273: 199–208
   Google Scholar
• Lip GYH, Beevers M, Churchill D, et al. Hormone replacement therapy and blood pressure in healthy postmenopausal women. J Hum Hypertens 1994; 8: 491–4
   PubMed Web of Science ®Google Scholar
• Van Ittersum F J, Van Baal W M, Kenemans P, et al. Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women. 1999, Am J Hypertensionin press
   Google Scholar
• Akkad A A, Halligan A W, Abrams K, et al. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol 1997; 89: 97–103
   PubMed Web of Science ®Google Scholar
• Adams M R, Kaplan J R, Kortnik D R, et al. Pregnancy-associated inhibition of coronary artery atherosclerosis in monkeys. Evidence of a relationship with endogenous estrogen. Arteriosclerosis 1987; 7: 378–84
   PubMedGoogle Scholar
• Krasinski K, Spyridopoulos I, Asahara T, et al. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997; 95: 1768–72
   PubMed Web of Science ®Google Scholar
• Meade T W, Mellows S, Bronzovic M, et al. Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533–7
   PubMed Web of Science ®Google Scholar
• Thompson S G, Kienast J, Pyke SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635–41
   PubMed Web of Science ®Google Scholar
• Vaughn D E, Declerck P J, Van Houte E, et al. Reactivated recombinant PAI-1 activity effectively prevents thrombolysis in vivo. Thromb Haemostas 1992; 68: 60–3
   PubMedGoogle Scholar
• Hamsten A, Wiman B, De Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–63
   PubMed Web of Science ®Google Scholar
• Zalewski A, Shi Y, Nardone D, et al. Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical and angiographic correlates. Circulation 1991; 83: 1685–91
   PubMedGoogle Scholar
• Nabulsi A A, Folsom A R, White A, et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069–75
   PubMed Web of Science ®Google Scholar
• Scarabin P Y, Plu-Bureau G, Bara L, et al. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemostas 1993; 70: 584–7
   PubMed Web of Science ®Google Scholar
• Heinrich J, Dirkes-Kersting A, Schulte H, et al. Effects of age, menopause and human growth hormone on variables of fibrinolysis. Fibrinolysis 1992; 6: 33–5
   Google Scholar
• Meade T W, Dyer S, Howarth D J, et al. Antithrombin III and procoagulant activity: sex differences and effects of menopause. Br J Haematol 1990; 74: 77–81
   PubMed Web of Science ®Google Scholar
• The writing group for the Estradiol Clotting Factors Study. Thromb Haemostas 1996; 75: 476–80, Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study.
   PubMed Web of Science ®Google Scholar
• Kroon U B, Silverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemostas 1994; 71: 420–3
   PubMedGoogle Scholar
• Kon Koh K, Mincemoyer R, Bui M N, et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683–90
   PubMedGoogle Scholar
• Caine Y G, Bauer K A, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemostas 1992; 68: 392–5
   PubMed Web of Science ®Google Scholar
• Saleh A A, Dorey L G, Dombrowski M P, et al. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 1993; 169: 1554–7
   PubMedGoogle Scholar
• Lowe GDO, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The third Glasgow MONICA survey. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775–84
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Goldhaber S Z, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–7
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey M P, Hawkins M M, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80
   PubMed Web of Science ®Google Scholar
• Jick H, Derby L E, Myers M W, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3
   PubMed Web of Science ®Google Scholar
• Devor M, Barrett Connor E, Renvall M, et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275–82
   PubMedGoogle Scholar
• Scanu A M, Lawn R M, Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991; 115: 209–18
   PubMed Web of Science ®Google Scholar
• Maher VMG, Brown B G. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229–35
   PubMed Web of Science ®Google Scholar
• Smith E B, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. Preferential immobilisation of lipoprotein (a). Atherosclerosis 1990; 84: 173–81
   PubMed Web of Science ®Google Scholar
• Hajjar K A, Gavish D, Breslow J L, et al. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature (London) 1989; 339: 303–4
   PubMed Web of Science ®Google Scholar
• Heinrich J, Sandkamp M, Kokott R, et al. Relationships of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37: 1950–4
   PubMed Web of Science ®Google Scholar
• Bruschi F, Meschia M, Soma M, et al. Lipoprotein (a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet Gynecol 1996; 88: 950–4
   PubMed Web of Science ®Google Scholar
• Berglund L. Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol 1995; 6: 48–56
   PubMedGoogle Scholar
• Soma M R, Fumagalli R, Paoletti R, et al. Effect of oestrogen and progestin on plasma Lp(a) levels in postmenopausal women. Lancet 1991; 3371: 612
   Google Scholar
• Soma M R, Osnago-Gadda I, Paoletti R, et al. The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993; 153: 1462–8
   PubMed Web of Science ®Google Scholar
• Van der Mooren M J, Demacker PNM, Thomas CMG, et al. A 2-year study on the beneficial effects of 17β-oestradiol–dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol 1993; 52: 117–23
   PubMed Web of Science ®Google Scholar
• Taskinen M R, Puolakka J, Pyorala T, et al. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol 1996; 16: 1215–21
   PubMed Web of Science ®Google Scholar
• Haines C, Chung T, Chang A, et al. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomised, double-blind, placebo-controlled, crossover study. Arch Intern Med 1996; 156: 866–72
   PubMed Web of Science ®Google Scholar
• Gelfand M M, Fugere P, Bissonnette F, et al. Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding. Menopause 1997; 4: 10–18
   Web of Science ®Google Scholar
• Mijatovic V, Kenemans P, Netelenbos J C, et al. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) in healthy postmenopausal women. J Clin Endocrinol Metab 1997; 82: 3543–7
   PubMed Web of Science ®Google Scholar
• Crook D, Sidhu M, Seed M, et al. Lipoprotein (a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992; 92: 41–7
   PubMed Web of Science ®Google Scholar
• Farish E, Rolton H A, Barnes J F, Hart D M. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. Br Med J 1991; 303: 694
   PubMed Web of Science ®Google Scholar
• Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein (a) in postmenopausal women. Acta Endocrinol (Copenh.) 1993; 128: 259–62
   PubMedGoogle Scholar
• Scanu A M, Fless G M. Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709–15
   PubMed Web of Science ®Google Scholar
• Clarke R, Daly L, Robinson K, et al. Hyper-homocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149–55
   PubMed Web of Science ®Google Scholar
• Stampfer M J, Malinow M R, Willett W C, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992; 268: 877–81
   PubMed Web of Science ®Google Scholar
• Boushey C J, Beresford SAA, Omenn G S, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049–57
   PubMed Web of Science ®Google Scholar
• Manilow M R. Homocysteine and arterial occlusive disease. J Intern Med 1994; 236: 603–17
   PubMedGoogle Scholar
• Wouters MGAJ, Moorees MTEC, Van der Mooren M L, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25: 801–5
   PubMed Web of Science ®Google Scholar
• Van der Mooren M J, Wouters MGAJ, Blom H J, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994; 24: 733–6
   PubMed Web of Science ®Google Scholar
• Van der Mooren M J, Wouters MGAJ, Blom H J, et al. Homocysteine: a new cardiovascular risk factor. Influences of menopause and hormone replacement. 1996, Presented at the 11th Congress of European Association of Gynaecologists and Obstetricians, Budapest, Hungary, June abstr. FC-2
   Google Scholar
• Van der Mooren M J, Demacker PNM, Blom H J, et al. The effects of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women. Fertil Steril 1997; 67: 67–73
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Kenemans P, Netelenbos J C, et al. Postmenopausal oral 17β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998; 69: 876–82
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Kenemans P, Jacobs C, et al. A randomized controlled study of the effects of 17β-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998; 91: 432–6
   PubMed Web of Science ®Google Scholar
• Kim M H, Kim E, Passen E L, et al. Cortisol and estradiol: nongenetic factors for hyperhomo-cysteinemia. Metabolism 1997; 46: 247–9
   PubMedGoogle Scholar
• Finkelstein J. Methionine metabolism in mammals. Effect of age, diet, and hormones on three enzymes of the pathway in rat tissues. Arch Biochem Biophys 1972; 122: 583–90
   Google Scholar
• Blom H J, Boers GHJ, Elzen JPAM, et al. Difference between premenopausal women and young men in the transamination pathway of methionine catabolism and the protection against vascular disease. Eur J Clin Invest 1988; 18: 633–8
   PubMedGoogle Scholar
• Giltay E J, Hoogeveen E K, Elbers JMH, et al. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 1998; 83: 550–3
   PubMedGoogle Scholar
• Peterson J C, Spence J D. Vitamins and progression of atherosclerosis in hyper-homocyst(e)-inaemia. Lancet 1998; 351: 263
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 104–59, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.
   Google Scholar
• Kauffman R F, Bryant H U. Selective estrogen receptor modulators. Drug News Perspect 1995; 8: 531–9
   Google Scholar
• Yang N N, Venugopalan M, Hardikar S, et al. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996; 273: 1222–5
   PubMed Web of Science ®Google Scholar
• Black L J, Sato M, Rowley E R, et al. Raloxifene (LY 139481) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1995; 93: 63–9
   Google Scholar
• Draper M W, Flowers D E, Huster W J, et al. A controlled trial of raloxifene (LY 139481) HCL: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835–42
   PubMed Web of Science ®Google Scholar
• Delmas P D, Bjarnason N H, Mitlak B H, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7
   PubMed Web of Science ®Google Scholar
• Walsh B W, Kuller L H, Wild R A, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998; 279: 1445–51
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Van der Mooren M J, Netelenbos J C, et al. Randomized, double-blind, placebo-controlled study on the effects of raloxifene and conjugated equine estrogen on plasma homocysteine in healthy postmenopausal women. Fertil Steril 1998; 70: 1085–9
   PubMed Web of Science ®Google Scholar
• McDonald C C, Alexander F E, Thyte B W, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 1995; 311: 977–80
   PubMed Web of Science ®Google Scholar
• McDonald C C, Stewart H J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 1991; 303: 435–7
   PubMed Web of Science ®Google Scholar
• Van der Mooren M J, Mijatovic V, Van Baal W M, et al. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas 1998; 30: 27–36
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Annu Rev Public Health 1998; 19: 55–72
   PubMed Web of Science ®Google Scholar
• Adams M R, Register T C, Golden D L, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 217–21
   PubMed Web of Science ®Google Scholar
• Register T C, Adams M R, Golden D L, et al. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998; 18: 1164–71
   PubMed Web of Science ®Google Scholar
• Espeland M A, Applegate W, Furgerg C D, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Am J Epidemiol 1996; 6: 314–23
   Google Scholar
• Akkad A, Hartshorne T, Bell PRF, et al. Carotid plaque regression on oestrogen replacement: a pilot study. Eur J Vasc Endovasc Surg 1996; 11: 347–8
   PubMedGoogle Scholar
• Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304–13
   PubMed Web of Science ®Google Scholar
• Beresford SAA, Weiss N S, Voight L F, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 53: 727–35
   Google Scholar